WordNet

(medicine) the act of caring for someone (as by medication or remedial training etc.); "the quarterback is undergoing treatment for a knee injury"; "he tried every treatment the doctors suggested"; "heat therapy gave the best relief"
aerobic rod-shaped spore-producing bacterium; often occurring in chainlike formations; found primarily in soil (同)B

PrepTutorEJDIC

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 膀胱内BCG免疫療法の合併症 complications of intravesical bcg immunotherapy
2. 筋層非浸潤性膀胱癌の治療 treatment of non muscle invasive bladder cancer
3. 尿路上皮（移行上皮）膀胱癌に対する根治的膀胱全摘除術および膀胱温存治療 radical cystectomy and bladder sparing treatments for urothelial transitional cell bladder cancer
4. 尿路上皮（移行上皮）膀胱癌のマネージメントの概要 overview of the management of urothelial transitional cell bladder cancer
5. 反応性関節炎（旧ライター症候群） reactive arthritis formerly reiter syndrome

Multiparametric MRI findings of granulomatous prostatitis after intravesical bacillus calmette-guérin therapy in a patient undergoing active surveillance.

Dianat SS1, Matoso A2, Carter BH3, Macura KJ4.
Clinical genitourinary cancer.Clin Genitourin Cancer.2014 Oct;12(5):e215-9. doi: 10.1016/j.clgc.2014.03.015. Epub 2014 Jun 10.
PMID 24999165

The effect of age on the efficacy of maintenance bacillus calmette-guérin relative to maintenance epirubicin in patients with stage ta t1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.

Oddens JR1, Sylvester RJ2, Brausi MA3, Kirkels WJ4, van de Beek C5, van Andel G6, de Reijke TM7, Prescott S8, Witjes JA9, Oosterlinck W10.
European urology.Eur Urol.2014 Oct;66(4):694-701. doi: 10.1016/j.eururo.2014.05.033. Epub 2014 Jun 16.
BACKGROUND: Although maintenance bacillus Calmette-Guérin (BCG) is the recommended treatment in high-risk non-muscle-invasive bladder cancer (NMIBC), its efficacy in older patients is controversial.OBJECTIVE: To determine the effect of age on prognosis and treatment outcome in patients with stage T
PMID 24948466

Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.

Rentsch CA1, Birkhäuser FD2, Biot C3, Gsponer JR1, Bisiaux A4, Wetterauer C1, Lagranderie M5, Marchal G5, Orgeur M6, Bouchier C7, Bachmann A8, Ingersoll MA9, Brosch R6, Albert ML10, Thalmann GN11.
European urology.Eur Urol.2014 Oct;66(4):677-88. doi: 10.1016/j.eururo.2014.02.061. Epub 2014 Mar 12.
BACKGROUND: Whether the commonly used bacillus Calmette-Guérin (BCG) strains Connaught and Tice confer different treatment responses in non-muscle-invasive bladder cancer (NMIBC) is unknown.OBJECTIVES: To compare clinical efficacy, immunogenicity, and genetics of BCG Connaught and Tice.DESIGN, SETT
PMID 24674149

松下慎,岡田宜之,洪陽子,王聡,氏家剛,任幹夫,辻畑正雄
泌尿器科紀要 = Acta urologica Japonica 60(6), 283-286, 2014-06
… A 85-year-old man achieved complete response after a course of intravesical instillation of Bacillus Calmette Guerin (BCG) therapy for carcinoma in situ (CIS) of the bladder. …
NAID 120005456035